Alvetex in Space
14 January 2016
While the first British ESA astronaut Tim Peake is currently on the International Space Station (ISS) and is about to make his first spacewalk, now is a good time to mention again that Reinnervate’s flagship product, Alvetex® Scaffold, has been used as part of a BBSRC-funded project on the ISS in recent months.
REPROCELL acquires Biopta to expand its drug discovery services
25 November 2015
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta.
Biopta co-authors research in the European Respiratory Journal
18 November 2015
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.
Publication of Paper on “3D culture model construction of mouse neurons” in Neuroscience Letters
18 November 2015
Reinnervate (now REPROCELL Europe) has written a paper on the topic of “3D culture model construction of mouse neurons”, along with other contributors including Durham University (UK), that has recently been published in ‘Neuroscience Letters’.
A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality
16 November 2015
“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
04 November 2015
REPROCELL like to inform you that a patent application concerning an amplification method of hematopoietic stem cells which we applied for jointly with Nissan Chemical Industries, Ltd., has passed screening in the United States.
REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others
19 October 2015
Read more about REPROCELL CSO Professor Stefan Przyborski's latest publication on 3D Skin Model Construction published in Molecular Cancer Therapeutics
The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal
14 October 2015
Group affiliate Stemgent Inc. (US) is pleased to announce the publication of a paper on state-of-the-art iPS cell production technology, entitled “RNA Reprogramming,” that was written collaboratively with the Whitehead Institute (USA).
REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells
08 September 2015
REPROCELL is pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.
Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free
26 August 2015
Read more about how REPROCELL's new high-performance cryopreservation solution ReproCryo (DMSO free) is advancing the field of regenerative medicine.
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
14 August 2015
REPROCELL would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large- Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).
Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”
29 July 2015
REPROCELL is pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons made from iPS cells derived from Alzheimer’s disease patients.
Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells
21 July 2015
This is a notice that we will on August 3rd 2015 commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.
Announcement of Award for Prototype Development of a Liver Cell Kit
01 July 2015
REPROCELL is pleased to announce that one of our projects, “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem (iPS) Cells for Applications in Drug Discovery” has been selected as a recipient of Grant for Manufacturing, Commerce, and Service Innovation additionally allocated for FY 2014-2015.
Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit
30 June 2015
Read REPROCELL Group company Stemgent inc.'s announcement of a New High Performance Self-replicative RNA Reprogramming Kit: Stemgent StemRNA™-SR
REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells
04 June 2015
Read about REPROCELLS exclusive distribution and licensing agreement with Keio University regarding myocardial cells originating from disease type iPS Cells
Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).
20 April 2015
Market leading 3D cell culture company Reinnervate Ltd, part of the ReproCELL group, today announced that a rocket carrying its Alvetex® Scaffold technology blasted into Space this week. Alvetex will be used in experiments on board the International Space Station (ISS).
New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system
05 March 2015
A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells.
RSC book publication: Human-based systems for translational research
02 February 2015
Read about the REPROCELL Europe CEO's newly published review of functional human tissue assays in a new book entitled Human-based systems for translational research
Biopta and Proteon publish new research in Journal of Cardiovascular Pharmacology
13 January 2015
A new paper in the Journal of Cardiovascular Pharmacology describes a potential treatment for atherosclerosis.